{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-281522","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.562626+00:00","generated_at":"2026-05-16T19:50:21.328584+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"TuHURA reports Q3 R&D $4.9M, cash burn $22.1M; Phase 3 MCC trial underway","bullets":["Phase 3 IFx-2.0 trial for MCC under SPA enrollment ongoing; topline results expected Q1 2027.","R&D expenses $4.9M (Q3 2025) vs $2.9M (Q3 2024); 9-month net cash outflow $22.1M vs $12.1M.","DOR technology selected for oral presentation at ASH 2025 Annual Meeting in December.","Appointed Dr. Michael Turner as Vice President of Immunology in November 2025.","Filed $50M ATM facility in November 2025; not yet effective."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-281522","json":"https://secwatch.observer/filing/0001193125-25-281522.json","markdown":"https://secwatch.observer/filing/0001193125-25-281522.md","text":"https://secwatch.observer/filing/0001193125-25-281522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525281522/0001193125-25-281522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525281522/hura-20251114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:50:21.328584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}